×
About 275 results

ALLMedicine™ Guttate Psoriasis Center

Research & Reviews  78 results

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434078
American Journal of Clinical Dermatology; Wu PC, Huang IH et. al.

Sep 2nd, 2022 - Vaccination has been promoted to control viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of psoriasis, an immune-mediated inflammatory disease, were reported following COVID-19...

A Sri Lankan infant with immunoglobulin resistant incomplete Kawasaki disease with a ve...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308020
BMC Pediatrics; Hoole TJ, Athapathu AS et. al.

Jul 24th, 2022 - Kawasaki disease (KD) is a medium and small vessel vasculitis which usually has a good response to immunoglobulin therapy (IVIG). We present a case of incomplete KD with IVIG resistance associated with an unusual combination of vesicular guttate-p...

Diffuse annular lesions
https://www.mdedge.com/familymedicine/article/256323/dermatology/diffuse-annular-lesions
MDedge Family Medicine; Clark Gravell, MD, Carly Dunn, MD et. al.

Jul 18th, 2022 - A 24-YEAR-OLD WOMAN with a history of guttate psoriasis, for which she was taking adalimumab, presented with a 2-week history of diffuse papules and plaques on her neck, back, torso, and upper and lower extremities (FIGURE 1). She said that the le.

Guttate Psoriasis Following COVID-19 Infection.
https://doi.org/10.12788/cutis.0443
Cutis Janodia RP, Kupetsky EA

Jun 7th, 2022 - Guttate psoriasis is a subgroup of psoriasis that most commonly presents as raindroplike, erythematous, silvery, scaly papules. Guttate psoriatic flares may follow rhinovirus or COVID-19 infection due to dysregulation of the innate immune response...

Guselkumab Immunogenetics
https://clinicaltrials.gov/ct2/show/NCT04645355

May 2nd, 2022 - Guselkumab (Tremfya®), an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Given the potential role of IL-23 in the pathogenesis of guttate psoriasis, guselkumab may be an effective option to treat the initial man...

see more →

Clinicaltrials.gov  6 results

Guselkumab Immunogenetics
https://clinicaltrials.gov/ct2/show/NCT04645355

May 2nd, 2022 - Guselkumab (Tremfya®), an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Given the potential role of IL-23 in the pathogenesis of guttate psoriasis, guselkumab may be an effective option to treat the initial man...

MED in UVB Devices in the Presence and Absence of UV Filter
https://clinicaltrials.gov/ct2/show/NCT03049319

Aug 29th, 2019 - Psoriasis affects 2-3% of the American population. Psoriasis involving less than 10% BSA in the absence of joint involvement tends to be treated locally. More than 80% of people with psoriasis have <10% BSA involvement. A wide variety of therapies...

Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis
https://clinicaltrials.gov/ct2/show/NCT03475914

Mar 23rd, 2018 - Twelve individuals with guttate psoriasis and 12 individuals with vulgaris psoriasis have been enrolled at Dermatological Unit of IRCCS Galeazzi Institute, Milan. Patients selected for the psoriasis vulgaris group had a course of disease stable fo...

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications
https://clinicaltrials.gov/ct2/show/NCT00427609

Apr 21st, 2015 - Psoriasis is a chronic, inflammatory skin disorder most commonly manifested by well-demarcated, erythematous and/or scaling plaques on the elbows, knees, scalp, and trunk. Psoriasis is a common disease with overall incidence of 1-3% of the general...

Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis
https://clinicaltrials.gov/ct2/show/NCT01000714

Oct 23rd, 2009 - Psoriasis is a chronic disorder characterized by erythematous scaly patches which affect the scalp, trunk, extensor surfaces of the limbs and the genital area. The common form of psoriasis is referred to as psoriasis vulgaris. There are several va...

see more →

News  26 results

Diffuse annular lesions
https://www.mdedge.com/familymedicine/article/256323/dermatology/diffuse-annular-lesions
MDedge Family Medicine; Clark Gravell, MD, Carly Dunn, MD et. al.

Jul 18th, 2022 - A 24-YEAR-OLD WOMAN with a history of guttate psoriasis, for which she was taking adalimumab, presented with a 2-week history of diffuse papules and plaques on her neck, back, torso, and upper and lower extremities (FIGURE 1). She said that the le.

COVID-19 infection linked to risk of cutaneous autoimmune and vascular diseases
https://www.mdedge.com/dermatology/article/253200/autoimmune-diseases/covid-19-infection-linked-risk-cutaneous-autoimmune
Doug Brunk

Mar 26th, 2022 - BOSTON – Following infection with SARS-CoV-2 infection, patients between the ages of 18 and 65 were at a significantly increased for developing certain cutaneous autoimmune and vascular diseases. This predominately favored systemic disease states.

Guttate Psoriasis Following COVID-19 Infection
https://www.mdedge.com/dermatology/article/251436/psoriasis/guttate-psoriasis-following-covid-19-infection
Rucha P. Janodia, BA, Erine A. Kupetsky, DO, MSc

Feb 4th, 2022 - Psoriasis is an inflammatory skin condition affecting 1% to 5% of the world population. 1 Guttate psoriasis is a subgroup of psoriasis that most commonly presents as raindroplike, erythematous, silvery, scaly papules.

Cutaneous Chaetomium globosum Infection in a Vedolizumab-Treated Patient
https://www.mdedge.com/dermatology/article/244500/infectious-diseases/cutaneous-chaetomium-globosum-infection-vedolizumab
Morgan Cronin, MD, Timothy G. Berger, MD et. al.

Aug 20th, 2021 - To the Editor: Broader availability and utilization of novel biologic treatments has heralded the emergence of unusual infections, including skin and soft tissue infections. These unusual infections may not be seen in clinical trials due to their.

Apremilast Uses and Relevance to the Military
https://www.mdedge.com/dermatology/article/238305/psoriasis/apremilast-uses-and-relevance-military
Nathanael E. Hathaway, MD, Willis Hughes Lyford, MD

Apr 7th, 2021 - Apremilast is a small-molecule biologic approved by the US Food and Drug Administration (FDA) for use in plaque psoriasis, psoriatic arthritis, and Behçet disease. 1-6 Although apremilast is seemingly a less favorable choice for treating psoriasis.

see more →